Who is sponsoring NCT05271916?

NCT05271916 is sponsored by Shanghai Chest Hospital.

What drugs are being tested in NCT05271916?

Interventions in NCT05271916: Dacomitinib+Anlotinib, Dacomitinib.

What condition does NCT05271916 study?

NCT05271916 studies Non-Small Cell Lung Cancer (NSCLC).

Is NCT05271916 still recruiting?

NCT05271916 is currently recruiting now. Last updated 19 April 2023.

Last reviewed 2023-04-19 · How we verify

NCT05271916

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations

Recruiting now Phase 1, PHASE2 Last updated 19 April 2023

What this trial tests

Phase 1, PHASE2 trial testing Dacomitinib+Anlotinib in Non-Small Cell Lung Cancer (NSCLC) in 140 participants. Currently enrolling.

Timeline

13 October 2022

Primary endpoint
1 January 2025

1 May 2027

Quick facts

Lead sponsor	Shanghai Chest Hospital
Phase	Phase 1, PHASE2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	140
Start date	13 October 2022
Primary completion	1 January 2025
Estimated completion	1 May 2027
Sites	1 location across China

Drugs / interventions tested

Dacomitinib+Anlotinib — full drug profile →
Dacomitinib (Dacomitinib) — full drug profile →

Conditions studied

Non-Small Cell Lung Cancer (NSCLC) — all drugs for Non-Small Cell Lung Cancer (NSCLC) →

Sponsor

Shanghai Chest Hospital

Who can join

Adults 18 to 75, any sex, with Non-Small Cell Lung Cancer (NSCLC). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multicenter, open label, Phase I/IIB study investigating the efficacy and safety of treatment with dacomitinib plus anlotinib as first-line therapy for patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) 21-L858R mutations. This study comprises two parts: 1. A dose escalation Phase I study to determine the recommended phase II dose. 2. a multi-center, open label, randomized controlled, Phase IIB study.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

New Generations of Tyrosine Kinase Inhibitors in Treating NSCLC with Oncogene Addiction: Strengths and Limitations.
Attili I, Corvaja C, Spitaleri G, Del Signore E, et al · · 2023 · cited 32× · PMID 37894445 · DOI 10.3390/cancers15205079

Verify or expand the search:

Other recruiting trials for Non-Small Cell Lung Cancer (NSCLC)

Currently open trials in the same condition.

NCT07361510 — A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced No · Phase 3 · recruiting
NCT07410494 — Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07510724 — Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab · recruiting
NCT06710132 — Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) · Phase 1, PHASE2 · recruiting
NCT06558799 — LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic · Phase 2 · active not recruiting

Other Shanghai Chest Hospital trials

Trials by the same sponsor.

NCT07515027 — Electroacupuncture Plus 5-HT3 Receptor Inhibitor for PONV Prevention in High-Risk Patients Undergoing Thoracoscopic Lung · NA · recruiting
NCT07479628 — Neoadjuvant Adebrelimab Plus CRT for Locally Advanced Thymic Carcinoma · Phase 2 · not yet recruiting
NCT07528066 — Downstaging and RATS After Neo-Chemo-IO: Impact on Surgical Outcomes in NSCLC · recruiting
NCT07331727 — Epicardial Adipose Tissue-Targeted DApagliflozin for Reducing Electrical Remodeling in Atrial Fibrillation · NA · not yet recruiting
NCT07320768 — Renal Denervation Combined With Pulsed Field Ablation to Prevent Blanking-Period Recurrence in Persistent Atrial Fibrill · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05271916 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Chest Hospital
Last refreshed: 19 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05271916.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing